Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers

ConclusionThe similar changes in exposure observed for participants with renal impairment, coupled with the known safety data from clinical experience, suggest that a lower starting dose of glasdegib may not be required for moderate or severe renal impairment.Trial registration: ClinicalTrials.gov: NCT03596567 (started May 17, 2018).

http://link.springer.com/10.1007/s00280-020-04207-9

Source: Cancer Chemotherapy and Pharmacology - January 3, 2021 Category: Cancer & Oncology Source Type: research